https://heartresearch.holy-cross.com---https://heartresearch.holy-cross.com/studies-list
Skip to Content
image description
  • image description
  • image description
  • image description

Studies List

Heart Failure with Preserved Ejection Fraction

CAPACITY


A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study Evaluating the Safety and Efficacy of Different Doses of IW-1973 over 12 Weeks in Patients with Heart Failure with Preserved Ejection Fraction

Principal Investigator: Joshua Larned, MD, FACC

Contact:
Mara-Li Ortiz, 954-229-8552, Mara-Li.Ortiz@holy-cross.com
Donovan Mott, 954-229-8571, Donovan.Mott@holy-cross.com

Acute Coronary Syndrome

AEGIS


A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects with Acute Coronary Syndrome

Principal Investigator: Joshua Purow, MD

Contact:
Angel Lescay, 954-267-6792, Angel.Lescay@holy-cross.com
Christine Lepurage, 954-229-8571, Christine.Lepurage@holy-cross.com

Atrial Fibrillation w/ ICD

ARTESIA


Apixaban for the Reduction of Thrombo-Embolism in patients with Device-Detected Sub-Clinical Atrial Fibrillation.

Principal Investigator: Rishi Anand, MD, FACC, FHRS

Contact:
Angel Lescay, 954-267-6792, Angel.Lescay@holy-cross.com
Christine Lepurage, 954-229-8571, Christine.Lepurage@holy-cross.com

Cardiovascular Disease

ESPERION CVD


A Randomized, Double-blind, Placebo-controlled Study to Assess the Effects of Bempedoic Acid  (ETC-1002) on the Occurrence of Major Cardiovascular Events in Patients with, or at high risk for, Cardiovascular Disease who are Statin Intolerant

Principal Investigator: Charles Russo, MD

Contact:
Donovan Mott, 954-229-8571, Donovan.Mott@holy-cross.com
Grey Sanchez, 954-229-8575, Grey.Sanchez@holy-cross.com

Congestive Heart Failure

CORVIA REDUCE Lap-HF

Evaluate the Corvia Medical, Inc. IASD System II to improve the quality of life and reduce heart failure related symptoms and events in patients with heart failure with preserved or mildly reduced ejection fraction (HFpEF) with elevated left atrial pressures, who remain symptomatic despite optimal GDMT

Principal Investigators: Joshua Larned, MD, FACC and Alexander Llanos, MD

Contact:
Angel Lescay, 954-267-6792, Angel.Lescay@holy-cross.com
Christine Lepurage, 954-229-8571, Christine.Lepurage@holy-cross.com

Heart Failure

VICTORIA HF


A Randomized Parallel-Group, Placebo-Controlled, Double-Blind, Event-Driven, Multi-Center Pivotal Phase III Clinical Outcome Trial of Efficacy and Safety of the Oral sGC Stimulator Vericiguat in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF) - VerICiguaT Global Study in Subjects With Heart Failure With Reduced Ejection Fraction

Principal Investigator: Joshua Larned, MD, FACC

Contact:
Angel Lescay, 954-267-6792, Angel.Lescay@holy-cross.com
Mara-Li Ortiz, 954-229-8552,  Mara-Li.Ortiz@holy-cross.com

Heart Failure

BeAT-HF


The Barostim BeAT-HF Pivotal study is a prospective, randomized, controlled trial of up to 480 subjects at up to 90 U.S. sites. Subjects will be randomized in a 1:1 ratio to receive a device plus optimal medical management or to receive optimal medical management alone.

Principal Investigators: Joshua Larned, MD, FACC and Irving David, MD

Contact:
Angel Lescay, 954-267-6792, Angel.Lescay@holy-cross.com
Christine Lepurage, 954-229-8571, Christine.Lepurage@holy-cross.com

HFrEF

CONNECT


Care Optimization throught patient and hospital engagement clinical trial for heart failure. Outcomes will be assessed in the year followng discharge for participants hospitalized with acute HF and history of reduced left ventricular ejection fraction.

Principal Investigator: Joshua Larned, MD, FACC

Contact:

Mara-Li Ortiz,  954-229-8552,  Mara-Li.Ortiz@holy-cross.com
Donovan Mott, 954-229-8571, Donovan.Mott@holy-cross.com

HFrEF

TRANSFORM


To compare torsemide versus furosemide on long-term clinical outcomes among patients hospitalized for heart failure.

Principal Investigator: Joshua Larned, MD, FACC

Contact:
Mara-Li Ortiz, 954-229-8552, Mara-Li.Ortiz@holy-cross.com
Donovan Mott, 954-229-8571, Donovan.Mott@holy-cross.com

ICD

ZOLL HEARIT - HF


Heart Sounds for Heart Failure Management in Patients Using the Wearable Cardioverter Defibrillator (HEARIT-HF) Study: the population for this study will be adult patients with documented heart failure during the index hospitalization, EF < 35% and eligible to wear the WCD for at least 3 months.

Principal Investigator: Joshua Larned, MD, FACC

Contact:
Angel Lescay, 954-267-6792, Angel.Lescay@holy-cross.com
or
Christine Lepurage, 954-229-8571, Christine.Lepurage@holy-cross.com

Ischemic Heart Failure

CONCERT


A Phase II, Randomized, Placebo-Controlled Study of the Safety, Feasibility, and Efficacy of Autologous Mesenchymal Stem Cells and c-kit+ Cardiac Stem Cells, Alone or in Combination, Administered Transendocardially in Subjects with Ischemic Heart Failure

Principal Investigator: Rishi Anand, MD

Contact:
Angel Lescay, 954-267-6792, Angel.Lescay@holy-cross.com

Human Heart

Holy Cross Hospital is committed to cutting-edge heart research and to offering the most advanced cardiac care in South Florida. Meet our team of principal investigators who are dedicated to providing the best cardiac care in our community.

Cancer Resources

More Cancer Resources

®2005-2011 WebMD, LLC. All rights reserved.

WebMD does not provide medical advice, diagnosis or treatment.

See additional information.

Request Info

Clinical Trial Info

Directions

image description

Studies

man getting heart procedure